Premature Ovarian Aging
After receiving a diagnosis of POAPOA , patients at CHR are given individualized treatment based on their ovarian reserve status and any other factors involved in their infertility condition. A good example is autoimmune abnormalities, which are often found in conjunction with POA.
"Our POA treatment program & high IVF pregnancy rates in POA patients separate CHR from other infertility centers."Dr. Norbert Gleicher
This individualized and proactive approach—born as a result of CHR's years of clinical research on POA and diminished ovarian reserve (DOR)—and our excellent IVF pregnancy rates even in patients with severe DOR are what separate CHR from most other IVF centers, and why we came to be known internationally as "the fertility center of last resort."
CHR's success in treating POA patients is partially a result of the introduction of DHEADHEA supplementation by CHR investigators. Today, a full decade later, DHEA is used worldwide! According to one survey, as of late 2010, more than one-third of the world's IVF centers have started using DHEA. However, DHEA is only a small part of CHR's comprehensive treatment approach to POA.
Comprehensive Treatment Approach to POA
Although the introduction of DHEA into fertility treatment for women with diminished ovarian reserve has revolutionized infertility treatment, especially for women with POA, DHEA alone has only limited beneficial effects. A successful, comprehensive fertility treatment paradigm for women with POA has at least three components:
- An ovarian stimulation protocol that is adjusted for individual patients' ovarian reserveovarian reserve ;
- Pre-stimulation supplementation with DHEA with androgenandrogen monitoring; and
- Highly individualized management of associated medical conditions
Let us explain a little more about DHEA (for a more detailed explanation, and a list of CHR's scientific publications on DHEA, please refer to our DHEA page).
DHEA is a mild male hormone. Once in the body, DHEA is converted to testosterone (an androgen, male hormone) and estradiol. For a number of years, CHR physicians have been using DHEA in women with DOR, whether ovarian impairment is due to advanced maternal age or premature ovarian aging. In doing so, we have been able to demonstrate that in such women, DHEA supplementation has quite remarkable beneficial effects, best summarized as rejuvenating ovarian function:
Benefits of DHEA on Female Fertility
- Increased IVF pregnancy rates
- Increased egg and embryo numbers
- Improved egg and embryo quality
- Reduced aneuploidy (chromosomal abnormalities) in embryos
- Reduced risks of miscarriages
- Shortened time to pregnancy
- Increased spontaneous conceptions
- Improved cumulative pregnancy rates in patients under fertility treatment
In recognition of these claims, CHR was awarded four DHEA-related U.S. patents (#7,615,544, #8,067,400, #8,501,718 and #8,501,719). For more details, please refer to our DHEA page.
Read more about Premature Ovarian Aging
Last Updated: November 15, 2014